Kessinger A, Vose J M, Bierman P J, Bishop M, Armitage J O
University of Nebraska Medical Center, Omaha 68198-3330.
J Hematother. 1993 Fall;2(3):361-2. doi: 10.1089/scd.1.1993.2.361.
Transplantation of circulating progenitor/stem cells collected before and stored during administration of marrow-ablative antitumor therapy has restored sustained hematopoiesis for patients with a variety of malignancies. One of the most common diseases so treated is refractory or relapsed non-Hodgkin's lymphoma (NHL). Autologous peripheral stem cell transplantation (PSCT) often has been used rather than autologous bone marrow transplantation (ABMT) because NHL commonly involves the bone marrow, and because, in some situations, PSCT provides earlier engraftment than ABMT. Between July 1986 and September 1992, 170 adult patients with refractory or relapsed NHL were treated with high-dose therapy and PSCT at the University of Nebraska Medical Center (UNMC). With a median follow-up of 469 days for the evaluable survivors, the actuarial progression-free survival for 167 patients at 6 years after PSCT was 30%. High-dose therapy and PSCT for NHL patients has resulted in long-term progression-free survival and probably cure for some patients. The role of PSCT in this disease continues to evolve.
在进行骨髓清除性抗肿瘤治疗前采集并在治疗期间储存的循环祖细胞/干细胞移植，已为患有各种恶性肿瘤的患者恢复了持续造血功能。接受这种治疗的最常见疾病之一是难治性或复发性非霍奇金淋巴瘤（NHL）。常采用自体外周干细胞移植（PSCT）而非自体骨髓移植（ABMT），原因是NHL通常累及骨髓，且在某些情况下，PSCT比ABMT能更早实现植入。1986年7月至1992年9月期间，内布拉斯加大学医学中心（UNMC）对170例难治性或复发性NHL成年患者进行了大剂量治疗和PSCT。可评估幸存者的中位随访时间为469天，167例患者在PSCT后6年的无进展生存率为30%。对NHL患者进行大剂量治疗和PSCT已带来长期无进展生存，且可能治愈部分患者。PSCT在这种疾病中的作用仍在不断演变。
